Placebo effects in allergen immunotherapy-An EAACI Task Force Position Paper.
Position Paper
allergen immunotherapy
allergy
clinical trials
methods
placebo effects
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
11
03
2020
accepted:
18
03
2020
pubmed:
24
4
2020
medline:
15
5
2021
entrez:
24
4
2020
Statut:
ppublish
Résumé
The placebo (Latin "I will please") effect commonly occurs in clinical trials. The psychological and physiological factors associated with patients' expectations about a treatment's positive and negative effects have yet to be well characterized, although a functional prefrontal cortex and intense bidirectional communication between the central nervous system and the immune system appear to be prerequisites for a placebo effect. The use of placebo raises certain ethical issues, especially if patients in a placebo group are denied an effective treatment for a long period of time. The placebo effect appears to be relatively large (up to 77%, relative to pretreatment scores) in controlled clinical trials of allergen immunotherapy (AIT), such as the pivotal, double-blind, placebo-controlled (DBPC) randomized clinical trials currently required by regulatory authorities worldwide. The European Academy of Allergy and Clinical Immunology (EAACI) therefore initiated a Task Force, in order to better understand the placebo effect in AIT and its specific role in comorbidities, blinding issues, adherence, measurement time points, variability and the natural course of the disease. In this Position Paper, the EAACI Task Force highlights several important topics regarding the placebo effect in AIT such as a) regulatory aspects, b) neuroimmunological and psychological mechanisms, c) placebo effect sizes in AIT trials, d) methodological limitations in AIT trial design and e) potential solutions in future AIT trial design. In conclusion, this Position Paper aims to examine the methodological problem of placebo in AIT from different aspects and also to highlight unmet needs and possible solutions for future trials.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
629-647Informations de copyright
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2010;1:CD003974.
Manchikanti L, Giordano J, Fellows B, Hirsch JA. Placebo and nocebo in interventional pain management: a friend or a foe-or simply foes? Pain Physician. 2011;14(2):157-175.
McQueen D, Cohen S, John-Smith P, Rampes H. Rethinking placebo in psychiatry: how and why placebo effects occur. Adv Psychiatr Treat. 2013;19(3):171-180.
McQueen D, Cohen S, John-Smith P, Rampes H. Rethinking placebo in psychiatry: the range of placebo effects. Adv Psychiatr Treat. 2013;19(3):162-170.
Murray D, Stoessl AJ. Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. Pharmacol Ther. 2013;140(3):306-318.
Meissner K, Kohls N, Colloca L. Introduction to placebo effects in medicine: mechanisms and clinical implications. Philos Trans R Soc Lond B Biol Sci. 2011;366(1572):1783-1789.
Jonas WB, Crawford C, Colloca L, et al. To what extent are surgery and invasive procedures effective beyond a placebo response? A systematic review with meta-analysis of randomised, sham controlled trials. BMJ Open. 2015;5(12):e009655. https://doi.org/10.1136/bmjopen-2015-009655
Benedetti F, Carlino E, Pollo A. How placebos change the patient's brain. Neuropsychopharmacology. 2011;36(1):339-354.
Frew AJ, Pfaar O. Placebo effects in allergen immunotherapy: an experts' opinion. Allergo J Int. 2018;27(6):162-166.
Beecher HK. The powerful placebo. J Am Med Assoc. 1955;159(17):1602-1606.
Schedlowski M, Enck P, Rief W, Bingel U. Neuro-bio-behavioral mechanisms of placebo and Nocebo responses: implications for clinical trials and clinical practice. Pharmacol Rev. 2015;67(3):697-730.
Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017;389(10088):2473-2481.
Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J Clin Lipidol. 2016;10(4):739-747.
del Cuvillo A, Sastre J, Bartra J, et al. Placebo effect in clinical trials involving patients with allergic rhinitis. J Investig Allergol Clin Immunol. 2011;21(Suppl 3):40-45.
Jutel M, Agache I, Bonini S, et al. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016;137(2):358-368.
Pfaar O, Bonini S, Cardona V, et al. Perspectives in allergen immunotherapy: 2017 and beyond. Allergy. 2018;73(Suppl 104):5-23.
Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798.
Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet. 1911;178(4594):814-817.
Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;177(4580):1572-1573.
Bruun E. Control examination of the specificity of specific desensitization in asthma. Acta Allergol. 1949;2(2):122-128.
Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet. 1954;266(6821):1055-1057.
German Society for Allergology and Clinical Immunology. http://www.dgaki.de/leitlinien/s2k-leitlinie-sit/. Accessed on 12 Feb, 2020.
Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M. The placebo effect in allergen-specific immunotherapy trials. Clin Transl Allergy. 2013;3(1):42.
European Medicines Agency (EMA). Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006.
European Medicines Agency (EMA). Guideline on the clinical investigation of medicinal products for the treatment of asthma. CHMP/EWP/2922/01 Rev.1.
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
European Agency for the Evaluation of Medicinal Products (EMEA). EMEA/CPMP position statement on the use of placebo in clinical trials with regard to the revised Declaration of Helsinki. EMEA/17424/01.
European Medicines Agency (EMA). Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available. EMA/759784/2010.
European Medicines Agency (EMA). ICH E10 Choice of control group in clinical trials CPMP/ICH/364/96.
European Medicines Agency (EMA). EMA/PDCO Standard Paediatric Investigation Plan for Allergen Products for Specific Immunotherapy. Revision 4. EMA/PDCO/737605/2009.
Juniper EF, Kline PA, Ramsdale EH, Hargreave FE. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1990;85(3):606-611.
Chelladurai Y, Suarez-Cuervo C, Erekosima N, et al. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. J Allergy Clin Immunol Pract. 2013;1(4):361-369.
Scadding GW, Calderon MA, Shamji MH, et al. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial. JAMA. 2017;317(6):615-625.
Klimek L, Sperl A, van Twuijver E, et al. A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations. Clin Transl Allergy. 2014;4:23.
Skierka AS, Michels KB. Ethical principles and placebo-controlled trials - interpretation and implementation of the Declaration of Helsinki's placebo paragraph in medical research. BMC Med Ethics. 2018;19(1):24.
Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001;344(21):1594-1602.
Kaptchuk TJ, Miller FG. Placebo Effects in Medicine. N Engl J Med. 2015;373(1):8-9.
Circassia Pharmaceuticals Press release, June 20, 2016: Top-line results from cat allergy phase III study. https://www.circassia.com/media/press-releases/circassia-announces-top-line-results-from-cat-allergy-phase-iii-study/. Accessed on 12 Feb, 2020.
Circassia Pharmaceuticals Press release, April 17, 2017: Top-line results from house dust mite allergy field study. https://www.circassia.com/media/press-releases/circassia-announces-top-line-results-from-house-dust-mite-allergy-field-study/. Accessed on 12 Feb, 2020.
Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov. 2013;12(3):191-204.
Petrie KJ, Rief W. Psychobiological mechanisms of placebo and Nocebo effects: pathways to improve treatments and reduce side effects. Annu Rev Psychol. 2019;70:599-625.
Rheker J, Winkler A, Doering BK, Rief W. Learning to experience side effects after antidepressant intake - Results from a randomized, controlled, double-blind study. Psychopharmacology. 2017;234(3):329-338.
Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet. 1978;2(8091):654-657.
Lieberman MD, Jarcho JM, Berman S, et al. The neural correlates of placebo effects: a disruption account. NeuroImage. 2004;22(1):447-455.
Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008;65(2):220-231.
Benedetti F, Arduino C, Costa S, et al. Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain. 2006;121(1-2):133-144.
Chavan SS, Pavlov VA, Tracey KJ. Mechanisms and therapeutic relevance of neuro-immune communication. Immunity. 2017;46(6):927-942.
Reardon C, Murray K, Lomax AE. Neuroimmune communication in health and disease. Physiol Rev. 2018;98(4):2287-2316.
Eccles R. The power of the placebo. Curr Allergy Asthma Rep. 2007;7(2):100-104.
Mansfield LE, Hampel F, Haeusler JM, Georges G. Study of levocetirizine in seasonal allergic rhinitis. Curr Med Res Opin. 2010;26(6):1269-1275.
Turnbull JW. Asthma conceived as a learned response. J Psychosom Res. 1962;6:59-70.
Gauci M, Husband AJ, Saxarra H, King MG. Pavlovian conditioning of nasal tryptase release in human subjects with allergic rhinitis. Physiol Behav. 1994;55(5):823-825.
Barrett JE, King MG, Pang G. Conditioning rhinitis in allergic humans. Ann N Y Acad Sci. 2000;917:853-859.
Goebel MU, Meykadeh N, Kou W, Schedlowski M, Hengge UR. Behavioral conditioning of antihistamine effects in patients with allergic rhinitis. Psychother Psychosom. 2008;77(4):227-234.
Vits S, Cesko E, Benson S, et al. Cognitive factors mediate placebo responses in patients with house dust mite allergy. PLoS ONE. 2013;8(11):e79576.
Kemeny ME, Rosenwasser LJ, Panettieri RA, Rose RM, Berg-Smith SM, Kline JN. Placebo response in asthma: a robust and objective phenomenon. J Allergy Clin Immunol. 2007;119(6):1375-1381.
Wechsler ME, Kelley JM, Boyd IO, et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med. 2011;365(2):119-126.
Kimata H. Kissing reduces allergic skin wheal responses and plasma neurotrophin levels. Physiol Behav. 2003;80(2-3):395-398.
Kimata H. Listening to mozart reduces allergic skin wheal responses and in vitro allergen-specific IgE production in atopic dermatitis patients with latex allergy. Behav Med. 2003;29(1):15-19.
Kimata H. Effect of viewing a humorous vs. nonhumorous film on bronchial responsiveness in patients with bronchial asthma. Physiol Behav. 2004;81(4):681-684.
Schafer SM, Geuter S, Wager TD. Mechanisms of placebo analgesia: A dual-process model informed by insights from cross-species comparisons. Prog Neurogibol. 2018;160:101-122.
Wedi B, Wieczorek D, Kapp A. Placebo effect in clinical trials with allergen-specific immunotherapy with inhalant allergens. Hautarzt. 2017;68(4):297-306.
Pfaar O, Bachert C, Bufe A, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014;23(8):282-319.
Masuyama K, Okamoto Y, Okamiya K, et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children. Allergy. 2018;73(12):2352-2363.
Abramowicz M, Kruszewski J, Chcialowski A. Evaluation of the placebo effect in the trials of allergen immunotherapy effectiveness: meta-analysis of randomized and placebo-controlled trials. Postepy Dermatol Alergol. 2018;35(6):620-625.
Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE 2010;5(12):e15591.
Charlesworth JEG, Petkovic G, Kelley JM, et al. Effects of placebos without deception compared with no treatment: A systematic review and meta-analysis. J Evid Based Med. 2017;10(2):97-107.
Schaefer M, Harke R, Denke C. Open-label placebos improve symptoms in allergic rhinitis: a randomized controlled trial. Psychother Psychosom. 2016;85(6):373-374.
Schaefer M, Sahin T, Berstecher B. Why do open-label placebos work? A randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis. PLoS ONE. 2018;13(3):e0192758.
Roche N, Reddel HK, Agusti A, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med. 2013;1(10):29-30.
Bousquet J, Anto JM, Demoly P, et al. Severe chronic allergic (and related) diseases: a uniform approach-a MeDALL-GA2LEN-ARIA Position Paper. Int Arch Allergy Immunol. 2012;158(3):216-231.
Ring J, Jutel M, Papadopoulos N, Pfaar O, Akdis C. Provocative proposal for a revised nomenclature for allergy and other hypersensitivity diseases. Allergy. 2018;73(10):1939-1940.
Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest. 1973;52(2):472-482.
Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy. J Allergy Clin Immunol. 1983;72(5 Pt 1):448-453.
Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004;59(1):45-53.
Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123(1):160-166.
Worm M, Rak S, de Blay F, et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy. 2014;4(1):7.
Slovick A, Douiri A, Muir R, et al. Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms. J Allergy Clin Immunol. 2017;139(6):1830-1839.
Incorvaia C, Mauro M, Leo G, Ridolo E. Adherence to Sublingual Immunotherapy. Curr Allergy Asthma Rep. 2016;16(2):12.
Senna G, Ridolo E, Calderon M, Lombardi C, Canonica GW, Passalacqua G. Evidence of adherence to allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol. 2009;9(6):544-548.
Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69(7):854-867.
Fauquert JL, Jedrzejczak-Czechowicz M, Rondon C, et al. Conjunctival allergen provocation test : guidelines for daily practice. Allergy. 2017;72(1):43-54.
Augé J, Vent J, Agache I, et al. EAACI Position paper on the standardization of nasal allergen challenges. Allergy. 2018;73(8):1597-1608.
Konstantinou GN, Xepapadaki P, Manousakis E, et al. Assessment of airflow limitation, airway inflammation, and symptoms during virus-induced wheezing episodes in 4- to 6-year-old children. J Allergy Clin Immunol. 2013;131(1):87-93.
Connell JT. Quantitative intranasal pollen challenges. 3. The priming effect in allergic rhinitis. J Allergy. 1969;43(1):33-44.
Murray CS, Poletti G, Kebadze T, et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax. 2006;61(5):376-382.
Xepapadaki P, Kostoudi S, Tzeli K, Kitsioulis N, Papadopoulos NG. A pilot study to investigate the influence of upper respiratory infections on IgE reactivity to food allergens. Pediatr Allergy Immunol. 2019;30(1):127-130.
Karatzas K, Katsifarakis N, Riga M, et al. New European Academy of Allergy and Clinical Immunology definition on pollen season mirrors symptom load for grass and birch pollen-induced allergic rhinitis. Allergy. 2018;73(9):1851-1859.
Pfaar O, Bastl K, Berger U, et al. Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis - an EAACI position paper. Allergy. 2017;72(5):713-722.
Karatzas K, Papamanolis L, Katsifarakis N, et al. Google Trends reflect allergic rhinitis symptoms related to birch and grass pollen seasons. Aerobiologia. 2018;34(4):437-444.
Karatzas K, Riga M, Berger U, Werchan M, Pfaar O, Bergmann KC. Computational validation of the recently proposed pollen season definition criteria. Allergy. 2018;73(1):5-7.
Buters J, Schmidt-Weber C, Oteros J. Next-generation pollen monitoring and dissemination. Allergy. 2018;73(10):1944-1945.
Tsilochristou OA, Douladiris N, Makris M, Papadopoulos NG. Pediatric allergic rhinitis and asthma: can the march be halted? Paediatr Drugs. 2013;15(6):431-440.
Bisgaard H, Bønnelykke K. Long-term studies of the natural history of asthma in childhood. J Allergy Clin Immunol. 2010;126(2):187-197; quiz 198-199.
Leibowitz KA, Hardebeck EJ, Goyer JP, Crum AJ. The role of patient beliefs in open-label placebo effects. Health Psychol. 2019;38(7):613-622.
European Medicines Agency (EMA). Guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials. EMA/CHMP/QWP/545525/2017.
Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):1-37.
Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.
Bousquet PJ, Brozek J, Bachert C, et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy. 2009;64(12):1737-1745.
Bousquet PJ, Calderon MA, Demoly P, et al. The consolidated standards of reporting trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol. 2011;127(1):49-56.
Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. 1996. Clin Orthop Relat Res. 2007;455:3-5.
Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013;131(5):1342-1349.
Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355(14):1445-1455.
Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125(1):131-138.
Frew AJ, Smith HE. Sublingual immunotherapy. J Allergy Clin Immunol. 2001;107(3):441-444.
Durham SR. The allergen-specificity of allergen immunotherapy - doubt no more. Allergy. 2019;74(11):2054-2056.
Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271-279.
Wagenmann M, Worm M, Akboga Y, Karjalainen M, Hohlfeld JM. Randomized immunotherapy trial in dual-allergic patients using "active allergen placebo" as control. Allergy. 2019;74(8):1480-1489.
Hedlin G, Wille S, Browaldh L, et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol. 1999;103(4):609-614.
Olsen OT, Larsen KR, Jacobsan L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy. 1997;52(8):853-859.
Pfaar O, Calderon MA, Andrews CP, et al. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper. Allergy 2017;72(7):1035-1042.
Couroux P, Patel D, Armstrong K, Larché M, Hafner RP. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy. 2015;45(5):974-981.
Pfaar O, Hohlfeld JM, Al-Kadah B, et al. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid. Clin Exp Allergy. 2017;47(11):1445-1455.
Rösner-Friese K, Kaul S, Vieths S, Pfaar O. Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs. J Allergy Clin Immunol. 2015;135(3):636-643.
Zieglmayer P, Focke-Tejkl M, Schmutz R, et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine. 2016;11:43-57.
Peyrin-Biroulet L, Lopez A, Sandborn W. Head-to-head Comparative Studies: Challenges and Opportunities? J Crohns Colitis. 2017;11(suppl_2):S567-S575.
Vieta E, Cruz N. Head to head comparisons as an alternative to placebo-controlled trials. Eur Neuropsychopharmacol. 2012;22(11):800-803.
Yang W, Zilov A, Soewondo P, Bech OM, Sekkal F, Home PD. Observational studies: going beyond the boundaries of randomized controlled trials. Diabetes Res Clin Pract. 2010;88(Suppl 1):S3-9.
Roche N, Campbell JD, Krishnan JA, et al. Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force. Clin Transl Allergy. 2019;9:20.
Bédard A, Basagaña X, Anto JM, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. J Allergy Clin Immunol. 2019;144(1):135-143.
Menditto E, Costa E, Midão L, et al. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. Clin Exp Allergy. 2019;49(4):442-460.
Bousquet J, Schunemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2019;145(1):70-80.
Bousquet J, Arnavielhe S, Bedbrook A, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy. 2018;8:45.
Bousquet J, Pfaar O, Togias A, et al. 2019 ARIA Care pathways for allergen immunotherapy. Allergy. 2019;74(11):2087-2102.
Frew AJ, DuBuske L, Keith PK, Corrigan CJ. Aberer W, Fischer von Weikersthal-Drachenberg KJ. Assessment of specific immunotherapy efficacy using a novel placebo score-based method. Ann Allergy Asthma Immunol. 2012;109(5):342-347.
Worm M, Rak S, Samoliński B, et al. Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension. Clin Exp Allergy. 2019;49(4):516-525.
Pfaar O, Bachert C, Kuna P, et al. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. J Allergy Clin Immunol. 2019;143(3):970-977.
Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529-538.
Okubo K, Masuyama K, Imai T, et al. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. J Allergy Clin Immunol. 2017;139(6):1840-1848.
Biedermann T, Kuna P, Panzner P, et al. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2019;143(3):1058-1066.
Frew AJ, Ljørring C, Wolf H, et al. Immunotherapy Study: Reanalysis by a combined symptom and medication score. J Allergy Clin Immunol. 2018;142(6):1998-1999.
Zieglmayer P, Nolte H, Nelson HS, et al. Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial. Ann Allergy Asthma Immunol. 2016;117(6):690-696.
Roux M, Devillier P, Yang WH, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. J Allergy Clin Immunol. 2016;138(2):451-458.
Nolte M, Barber D, Maloney J, et al. Timothy specific IgE levels are associated with efficacy and safety of timothy grass sublingual immunotherapy tablet. Ann Allergy Asthma Immunol. 2015;115(6):509-515.
Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131(1):103-109.
Meyer W, Narkus A, Salapatek AM, Häfner D. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy. 2013;68(6):724-731.
Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009;124(3):471-477.